Year |
Citation |
Score |
2016 |
Yang C, Ford ME, Tilley BC, Greene RL. Religiosity in black and white older Americans: Measure adaptation, psychometric validation, and racial difference. Medicine. 95: e4257. PMID 27631201 DOI: 10.1097/Md.0000000000004257 |
0.46 |
|
2015 |
Simuni T, Kieburtz K, Tilley B, J Elm J, Ravina B, Babcock D, Emborg M, Hauser R, Kamp C, Morgan JC, Webster Ross G, K Simon D, Bainbridge J, Baker L, Bodis-Wollner I, et al. Pioglitazone in early Parkinson's disease: A phase 2, multicentre, double-blind, randomised trial The Lancet Neurology. 14: 795-803. DOI: 10.1016/S1474-4422(15)00144-1 |
0.34 |
|
2014 |
Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. Jama Neurology. 71: 710-6. PMID 24711047 DOI: 10.1001/Jamaneurol.2014.391 |
0.325 |
|
2013 |
Emberson J, Lees KR, Howard G, Bluhmki E, Tilley B, Albers G, Baigent C, Blackwell L, Davis S, Donnan G, Grotta J, Hacke W, Kaste M, von Kummer R, Lansberg M, et al. Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: Statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis International Journal of Stroke. 8: 278-283. PMID 23639145 DOI: 10.1111/Ijs.12040 |
0.312 |
|
2013 |
Antonini A, Abbruzzese G, Ferini-Strambi L, Tilley B, Huang J, Stebbins GT, Goetz CG, Barone P, Bandettini di Poggio M, Fabbrini G, Di Stasio F, Tinazzi M, Bovi T, Ramat S, et al. Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 34: 683-7. PMID 22678179 DOI: 10.1007/S10072-012-1112-Z |
0.326 |
|
2012 |
Yang C, Selassie AW, Carter RE, Tilley BC. Measuring Quality of Life with SF-36 in Older Americans with Traumatic Brain Injury. Applied Research in Quality of Life. 7: 63-81. PMID 25411585 DOI: 10.1007/S11482-011-9148-4 |
0.453 |
|
2012 |
Seidel SE, Tilley BC, Huang P, Palesch YY, Bergmann KJ, Goetz CG, Swearingen CJ. Subject-investigator reproducibility of the Unified Parkinson's Disease Rating Scale. Parkinsonism & Related Disorders. 18: 230-3. PMID 22018910 DOI: 10.1016/J.Parkreldis.2011.10.006 |
0.548 |
|
2012 |
Homayoun H, Stebbins G, Tilley B, Goetz C. Fatigue in Parkinson's Disease (P06.052) Neurology. 78: P06.052-P06.052. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P06.052 |
0.306 |
|
2011 |
Swearingen CJ, Tilley BC, Adams RJ, Rumboldt Z, Nicholas JS, Bandyopadhyay D, Woolson RF. Application of beta regression to analyze ischemic stroke volume in NINDS rt-PA clinical trials. Neuroepidemiology. 37: 73-82. PMID 21894044 DOI: 10.1159/000330375 |
0.507 |
|
2010 |
Högl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B, Trenkwalder C, Poewe W, Rascol O, Sampaio C, Stebbins GT, Schrag A, Goetz CG. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 2704-16. PMID 20931631 DOI: 10.1002/Mds.23190 |
0.307 |
|
2009 |
Parashos SA, Swearingen CJ, Biglan KM, Bodis-Wollner I, Liang GS, Ross GW, Tilley BC, Shulman LM. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Archives of Neurology. 66: 1099-104. PMID 19597081 DOI: 10.1001/Archneurol.2009.159 |
0.593 |
|
2009 |
Yang C, Garrett-Mayer E, Schneider JS, Gollomp SM, Tilley BC. Repeatable battery for assessment of neuropsychological status in early Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 1453-60. PMID 19452561 DOI: 10.1002/Mds.22552 |
0.522 |
|
2009 |
Schneider MG, Swearingen CJ, Shulman LM, Ye J, Baumgarten M, Tilley BC. Minority enrollment in Parkinson's disease clinical trials. Parkinsonism & Related Disorders. 15: 258-62. PMID 18693062 DOI: 10.1016/J.Parkreldis.2008.06.005 |
0.58 |
|
2009 |
Elm J, Bergmann K, Tilley B, Goudreau J, Salak V, Weiner W, Aminoff M, Shulman L, Cambi F, Kieburtz K, Net-Pd. P1.127 Parkinson's disease subtypes and their relevance to studies of disease-modifying agents Parkinsonism & Related Disorders. 15. DOI: 10.1016/S1353-8020(09)70249-4 |
0.304 |
|
2008 |
Carlozzi NE, Horner MD, Yang C, Tilley BC. Factor analysis of the Repeatable Battery for the Assessment of Neuropsychological Status. Applied Neuropsychology. 15: 274-9. PMID 19023744 DOI: 10.1080/09084280802325124 |
0.451 |
|
2008 |
Simon DK, Swearingen CJ, Hauser RA, Trugman JM, Aminoff MJ, Singer C, Truong D, Tilley BC. Caffeine and progression of Parkinson disease. Clinical Neuropharmacology. 31: 189-96. PMID 18670242 DOI: 10.1097/Wnf.0B013E31815A3F03 |
0.581 |
|
2008 |
Kieburtz K, Tilley B, Ravina B, Galpern W, Shannon K, Tanner C, Wooten GF. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-Month results Clinical Neuropharmacology. 31: 141-150. PMID 18520981 DOI: 10.1097/Wnf.0B013E3181342F32 |
0.388 |
|
2007 |
Kieburtz K, Ravina B, Galpern WR, Tilley B, Shannon K, Tanner C, Wooten GF, Hamill R, Sage JI, Kosa E, Watts RL, Stover NR, McMurray R, Lew MF, Kawai C, et al. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease Neurology. 68: 20-28. PMID 17200487 DOI: 10.1212/01.Wnl.0000250355.28474.8E |
0.404 |
|
1994 |
Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, Haley EC, Grotta J, Marler J. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke; a Journal of Cerebral Circulation. 25: 2220-6. PMID 7974549 DOI: 10.1161/01.Str.25.11.2220 |
0.313 |
|
1992 |
Tilley B. A deming approach to recruiting: The National Institute of Neurological disorders and stroke (NINDS) t-PA stroke trial experience Controlled Clinical Trials. 13: 428-429. DOI: 10.1016/0197-2456(92)90167-X |
0.312 |
|
Show low-probability matches. |